The objective of this study is to determine whether continuous infusion of ceftazidime-avibactam (CAZ-AVI) could improve clinical outcomes in critically ill patients compared with intermittent infusion.
18-85 years old, male or female.
Patients who are admitted to ICU wards.
Patients clinically diagnosed with carbapenem-resistant organism (CRO) infections, and has been commenced on targeted therapy with ceftazidime-avibactam.
One or more organ dysfunction criteria in the previous 24 hours i. MAP < 60 mmHg for at least 1 hour; ii. Vasopressors required for > 4 hours; iii. Respiratory support using supplemental high flow nasal prongs, continuous positive airway pressure, bilevel positive airway pressure or invasive mechanical ventilation for at least 1 hour.
Patient has a known allergy to ceftazidime-avibactam.
Patient has received ceftazidime-avibactam for more than 48 hours during current infectious episode.
Patient is in severe condition or expected to survive for no more than 48 hours.
Patient who receives lung or heart transplant or stem cell transplant.